KdT Ventures

PHNX Materials is a manufacturing enterprise that converts industrial waste into valuable resources, primarily targeting the construction sector. It collects waste products like fly ash from power plants and slag from steel mills, processes these materials, and integrates them into concrete mixtures, substituting a portion of traditional cement. This process helps reduce greenhouse gas emissions, lower costs, and maintain or even enhance concrete performance, thereby aiding the construction industry's decarbonization efforts.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Montara Therapeutics is a biotechnology company that focuses on developing a precision pharmacology platform aimed at creating innovative therapies for central nervous system diseases. By leveraging human genetics and machine learning, the company identifies and validates drug targets, which enhances the ability of medical professionals to deliver safe and effective treatments for patients suffering from neurological disorders. Montara Therapeutics' approach is designed to improve therapeutic outcomes and address unmet medical needs in the field of neurology.

Reverb Therapeutics focuses on developing innovative treatments for cancer and other diseases through advanced cytokine therapy. The company specializes in using bispecific antibodies to target and localize endogenous cytokines to immune cells within the tumor microenvironment. This approach aims to enhance targeted immune activation while minimizing the toxicity commonly associated with exogenously delivered cytokines. By leveraging the body's own cytokines, Reverb Therapeutics seeks to improve treatment outcomes for cancer patients, offering a promising alternative in the healthcare sector.

MacroCycle Technologies is a company developing a chemical recycling process to convert polyethylene terephthalate (PET) and polyester-fiber waste into virgin-grade plastics. Their proprietary technology, based on synthesizing cyclic macromolecules, enables the production of recycled PET with lower energy use than traditional methods. This process offers a sustainable, zero-carbon, and cost-competitive solution for plastic upcycling, contributing to a circular economy.

Shiprocket is an eCommerce shipping platform based in New Delhi, India, that was founded in 2017. The company specializes in providing cost-effective shipping solutions for direct-to-consumer retailers. Shiprocket's platform utilizes a machine-learning-based data engine to recommend appropriate courier services, select courier companies, print shipping labels, and track orders from a unified interface. This functionality allows businesses to efficiently manage their shipping and returns processes. Additionally, Shiprocket Packaging offers high-quality packaging materials with a focus on on-time delivery across India, catering to brands and businesses of all sizes.

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

Montara Therapeutics is a biotechnology company that focuses on developing a precision pharmacology platform aimed at creating innovative therapies for central nervous system diseases. By leveraging human genetics and machine learning, the company identifies and validates drug targets, which enhances the ability of medical professionals to deliver safe and effective treatments for patients suffering from neurological disorders. Montara Therapeutics' approach is designed to improve therapeutic outcomes and address unmet medical needs in the field of neurology.

Marigold Health operates a social network community platform that provides AI-augmented chat support groups designed to assist individuals with behavioral health needs. By facilitating anonymous text-based group therapies, the company enables patients dealing with mental health and substance use conditions to connect and support one another. These support groups are complemented by the involvement of recovery coaches who help participants formulate personalized recovery plans. Marigold Health partners with treatment providers and managed care organizations within the Medicaid market, aiming to enhance patient engagement while allowing care teams to manage increased capacity effectively. Through its innovative approach, the company offers on-demand, stigma-free support for individuals seeking to improve their mental health.

Radar Therapeutics is a pioneering company specializing in precision-expressed mRNA-based therapeutics designed to combat pathogenic cells by targeting their unique transcriptional signatures. The company has developed advanced ribonucleic acid sensing technology, which incorporates control elements for creating rationally designed, precise, and programmable therapies. This innovative approach allows for the targeting of previously undruggable therapeutic targets, enabling healthcare professionals to administer treatments that can either eliminate or reprogram specific pathogenic cells effectively. Through its groundbreaking advancements, Radar Therapeutics aims to provide novel solutions for complex diseases, fundamentally changing the landscape of therapeutic development.

Founded in 2017 by Dr. Matthew Hill, Elegen is a biotechnology company specializing in microfluidic technology for the development of advanced DNA synthesizers. Its mission is to accelerate biomedical progress through innovative synthetic biology solutions.

Motif Neurotech specializes in developing minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses, focusing initially on treatment-resistant depression. The company aims to restore hope and improve quality of life by providing personalized treatments that repair neural circuits.

ZymoChem, Inc. is a biotechnology company based in Emeryville, California, founded in 2013. The company specializes in developing microbes and bioprocesses that convert renewable feedstocks, such as sugars, into bio-based chemicals. ZymoChem's innovative platform focuses on creating eco-friendly chemical solutions while minimizing carbon dioxide emissions during production. By engineering novel microbes and establishing cost-effective bioprocesses, the company enhances the biological conversion of renewable materials into various industrial chemicals. This approach not only lowers production costs for clients but also contributes to sustainability by promoting a carbon-efficient manufacturing process. ZymoChem aims to support the transition to a real-zero economy by providing alternatives that reduce carbon emissions across product development, usage, and disposal.

Aperiam Bio, founded in 2021 and based in Austin, Texas, specializes in the development of industrial and therapeutic proteins. The company collaborates with enzyme engineers and distributors to produce stabilized, solubilized, and catalytically optimized proteins. Utilizing advanced deep learning optimization and proprietary algorithms, Aperiam Bio identifies critical components of protein chemistry to discover novel gain-of-function mutations. This innovative approach allows the engineering of biological molecules aimed at enhancing agricultural and pharmaceutical applications. By focusing on hyper-folded proteins, Aperiam Bio enables researchers to create more effective and durable proteins than those found in nature, ultimately contributing to advancements in various fields and improving lives.

SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.

Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.

Dimension Inx Corp., established in 2016 and based in Chicago, Illinois, specializes in designing and developing advanced biomaterials for research and commercial applications. The company focuses on creating three-dimensional (3D) printable materials and objects that mimic natural tissues, aiming to restore tissue and organ function. Dimension Inx's portfolio includes products such as Hyperelastic bone, 3D graphene, fluffy-x, and tissue papers, all designed to facilitate regenerative medicine and medical device applications. The company's unique biomaterials platform considers the intricate interplay between material composition, microstructure, and microarchitecture to produce biofunctionality within the body, enabling clinicians to promote self-healing without resorting to organ transplantation.

Onc.AI, Inc. is a technology company founded in 2020 and headquartered in San Carlos, California. It specializes in clinical oncology, utilizing advanced software that integrates genomics, proteomics, and radiomics to enhance oncology diagnostics. By employing deep learning techniques, Onc.AI aims to provide actionable insights that improve treatment outcomes for cancer patients. The company's innovative approach seeks to advance the field of oncology through the development of comprehensive data-driven solutions.

Asimov designs and develops biologics and gene therapies, focusing on mammalian cell engineering and genetic circuit design. The company combines synthetic biology, computer-aided design, and machine learning to accelerate the design and manufacture of biologics, viral vectors, and cell and gene therapies. Its platform integrates biophysical simulations with data-driven models of biology to engineer genetic circuits and optimize production processes. Founded in 2017 and based in Cambridge, Massachusetts, Asimov supports healthcare firms in advancing therapeutic pipelines through software and engineering tooling that bridges biology and computational design.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.

Equii is a food technology company that discovers nutritious microbial proteins from various sources. These are used to ferment grains, resulting in high-protein grain flours.

Tavros Therapeutics is a biotechnology company based in Durham, North Carolina, focused on discovering and developing therapies for cancer. Founded in 2019, the company aims to advance oncology treatments by identifying vulnerabilities within tumors. This approach allows for targeted drug combinations, potentially improving outcomes for patients with oncological diseases.

Canaery is developing a neural interface that analyzes an object's scent fingerprint to identify dangerous compounds at ports and inspection points, potentially replacing or supplementing x-ray and camera methods. The company aims to digitize the sense of scent through a neurotech device that interprets scents entering an olfactory system and prioritizes those relevant to customers, enabling the identification of hazardous compounds and the underlying object or its state. By translating olfactory information into actionable signals, Canaery seeks to enhance security and inspection efficiency in high-risk environments.

Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

Unravel Biosciences is a therapeutics company spun out from the Wyss Institute at Harvard University. It develops therapies for complex disorders by repurposing existing drugs to discover and clinically validate new targets. The company combines a proprietary large action model of human health with rapid in vivo screening and clinical validation to uncover drug targets and derisk novel biology faster and more cost-effectively than traditional approaches. Its platform integrates computational drug prediction with on-demand animal models and screening tools to link behavioral and cognitive symptoms to targets and treatments. The business has progressed discoveries into several clinical trials and has built partnerships through its rareSHIFT services to expand its therapeutic pipeline, intellectual property, and access to clinical samples.

Zeta Surgical is a digital surgery company dedicated to enhancing the accuracy, safety, and accessibility of image-guided procedures. It has developed an advanced navigation and robotics platform that utilizes computer vision and artificial intelligence to provide real-time image guidance at the point-of-care. This technology enables the overlay of 3D anatomical images, such as ultrasound and CT scans, directly within patients, while simultaneously tracking the positions of surgical instruments. By improving the visualization of surgical environments, Zeta Surgical's tools facilitate more effective and safer operations across various medical fields, including emergency care and interventional medicine. Founded by Harvard graduates and faculty, the company collaborates with leading hospitals and universities to advance its innovative solutions.

Founded in 2018, Terray Therapeutics is a biotechnology company based in Pasadena, California. It integrates experimentation and computation to enhance small molecule drug discovery, focusing on intractable diseases. The company's platform generates precise data through a rapid design-make-test-analyze cycle, enabling efficient exploration of chemical space.

Marigold Health operates a social network community platform that provides AI-augmented chat support groups designed to assist individuals with behavioral health needs. By facilitating anonymous text-based group therapies, the company enables patients dealing with mental health and substance use conditions to connect and support one another. These support groups are complemented by the involvement of recovery coaches who help participants formulate personalized recovery plans. Marigold Health partners with treatment providers and managed care organizations within the Medicaid market, aiming to enhance patient engagement while allowing care teams to manage increased capacity effectively. Through its innovative approach, the company offers on-demand, stigma-free support for individuals seeking to improve their mental health.

Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

Synteny.Ai Syntney decodes the signals of immune repertoires to help biotech research and pharma companies with disease discoveries.

Greeneye Technology develops AI-powered precision agriculture solutions that transform weed control by enabling real-time, selective herbicide spraying. Its proprietary selective spraying system turns standard sprayers into smart machines by detecting weeds and applying herbicides only where needed, reducing herbicide usage by up to 90%. Founded in 2017 and based in Tel Aviv, Israel, the company brings expertise across computer vision, artificial intelligence, agronomy, mechanical engineering, and spraying applications to help farmers implement sustainable, data-informed crop protection. The technology supports field insights and automated decision making to optimize spray applications, enabling farmers to lower chemical inputs while maintaining effective pest control.

ZymoChem, Inc. is a biotechnology company based in Emeryville, California, founded in 2013. The company specializes in developing microbes and bioprocesses that convert renewable feedstocks, such as sugars, into bio-based chemicals. ZymoChem's innovative platform focuses on creating eco-friendly chemical solutions while minimizing carbon dioxide emissions during production. By engineering novel microbes and establishing cost-effective bioprocesses, the company enhances the biological conversion of renewable materials into various industrial chemicals. This approach not only lowers production costs for clients but also contributes to sustainability by promoting a carbon-efficient manufacturing process. ZymoChem aims to support the transition to a real-zero economy by providing alternatives that reduce carbon emissions across product development, usage, and disposal.

Founded in 2017 by Dr. Matthew Hill, Elegen is a biotechnology company specializing in microfluidic technology for the development of advanced DNA synthesizers. Its mission is to accelerate biomedical progress through innovative synthetic biology solutions.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.

Debut Biotechnology, Inc. is a biotechnology company based in San Diego, California, established in 2019. It specializes in biomanufacturing solutions for high-value molecules, focusing on the development of specialty enzyme solutions and continuous manufacturing processes. The company offers a range of services, including biomanufacturing cartridges, fermentation, and the immobilization of cells and enzymes. Debut Biotechnology is dedicated to creating novel immobilization techniques for enzymes, achieving high success rates and providing immobilized enzymes for continuous manufacturing systems. Its innovative approach enables the production and modification of small and large molecules, catering primarily to the pharmaceutical and specialty chemical industries. By harnessing natural enzyme technologies, Debut aims to deliver sustainable and cost-effective ingredient solutions to its clients.

Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.

Modulus Therapeutics is a company focused on developing immune cell therapies specifically aimed at treating solid tumors. Leveraging advanced artificial intelligence and machine learning, the company designs optimized cell therapies through genetic engineering. This innovative approach allows for the creation of targeted treatments that address cancer and other serious diseases, ultimately improving patient outcomes. Modulus Therapeutics aims to enhance the effectiveness of cell therapies by harnessing technology to personalize and refine treatment options.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Founded in 2018, Dyno Therapeutics specializes in developing adeno-associated virus (AAV) vectors for in vivo gene therapy delivery. The company's proprietary platform combines DNA synthesis of AAV capsids with sequencing and machine learning to create novel vectors tailored for safe, efficient, and targeted therapeutic solutions.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, that focuses on developing gene therapies to enhance health and extend the lifespans of dogs and other domesticated animals. Founded in 2017, the company utilizes innovative approaches derived from research at the Wyss Institute at Harvard Medical School to create anti-aging therapies and address age-related diseases. By introducing new DNA instructions into the bodies of pets, Rejuvenate Bio aims to offer solutions for chronic conditions and improve overall well-being. The company's gene therapy pipeline is designed to target specific diseases and leverage clinically validated gene targets to ensure effective and lasting results.

SeQure DX is a biotechnology company specializing in genomics diagnostics for CRISPR-based gene editing therapies. It develops technologies that identify potential off-target sites prior to therapy initiation, ensuring comprehensive confirmation of actual edits. This enables safer and more effective gene editing therapeutics development, benefiting both researchers and patients.

Theator Inc. is a company that specializes in developing a surgical intelligence platform designed to enhance surgeon performance through the use of artificial intelligence and computer vision. Founded in 2018 and based in San Mateo, California, Theator offers a product known as Minutes, which includes content management software and a visual operative report with analytics. This platform analyzes and houses video data from surgical procedures, allowing surgeons to review and learn from past surgeries for educational purposes. By extracting and annotating key moments from real-world procedures, Theator empowers surgeons to gain insights into their performance and fosters a culture of continuous improvement in the operating room. The company's partnerships with innovative surgeons and hospitals aim to create a more transparent surgical environment while elevating surgical expertise.

Onc.AI, Inc. is a technology company founded in 2020 and headquartered in San Carlos, California. It specializes in clinical oncology, utilizing advanced software that integrates genomics, proteomics, and radiomics to enhance oncology diagnostics. By employing deep learning techniques, Onc.AI aims to provide actionable insights that improve treatment outcomes for cancer patients. The company's innovative approach seeks to advance the field of oncology through the development of comprehensive data-driven solutions.

Dimension Inx Corp., established in 2016 and based in Chicago, Illinois, specializes in designing and developing advanced biomaterials for research and commercial applications. The company focuses on creating three-dimensional (3D) printable materials and objects that mimic natural tissues, aiming to restore tissue and organ function. Dimension Inx's portfolio includes products such as Hyperelastic bone, 3D graphene, fluffy-x, and tissue papers, all designed to facilitate regenerative medicine and medical device applications. The company's unique biomaterials platform considers the intricate interplay between material composition, microstructure, and microarchitecture to produce biofunctionality within the body, enabling clinicians to promote self-healing without resorting to organ transplantation.

Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.

Abridge is a healthcare technology company that uses generative AI to automate transcription and summarization of medical conversations. The platform turns patient-clinician discussions into structured clinical notes in real time and integrates with electronic health record systems. By reducing manual note-taking, it helps clinicians capture key details while producing clear summaries for patients, and ensures documentation is added to patient records. Abridge emphasizes data security and patient privacy, complies with healthcare regulations, and provides a customizable interface aligned with clinical workflows and patient needs.

Rarebird is a coffee company that specializes in producing coffee products designed to enhance mental wellness. Utilizing Arabica coffee beans, the company incorporates bioactive ingredients, specifically a caffeine replacement compound called paraxanthine, which is backed by research to improve alertness while minimizing jitteriness and anxiety. Rarebird places a strong emphasis on ethical and sustainable sourcing by partnering with third-party coffee suppliers, ensuring that their beans are procured responsibly. This approach not only prioritizes the well-being of consumers but also adds value for coffee producers.

Remedy Robotics is a developer of innovative remote-controlled endovascular robots aimed at improving access to medical interventions worldwide. The company specializes in automating the procedure of mechanical thrombectomy, a crucial treatment for stroke patients. By enhancing the efficiency and effectiveness of endovascular interventions, Remedy Robotics seeks to ensure timely care, ultimately reducing the risk of severe disabilities resulting from strokes. Through its advancements in robotic technology, the company is committed to transforming the landscape of emergency medical care.

Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.

Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.

Solugen, Inc. is a specialty chemicals company based in Houston, Texas, founded in 2016. It focuses on producing industrial chemicals through the application of biotechnology and green chemistry, specifically utilizing plant-derived substitutes to replace petroleum-based products. The company offers a range of products, including BioPeroxide, a carbon-negative hydrogen peroxide, and BioChelate, a biodegradable chelant. Other offerings include ScavSol, a multivalent metal sequestrant for energy applications, ScaleSol, an alternative to phosphonates for scale control, and CorrSol, which addresses corrosion and fouling. Solugen's innovative approach combines fermentation and petrochemical processing along with advancements in synthetic biology and enzymatic technology, enabling it to create environmentally friendly chemicals from bio-based feedstocks. Its solutions cater to diverse industries such as agriculture, cleaning, energy, and water, contributing to reduced costs and lower carbon emissions while promoting sustainability.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.

Debut Biotechnology, Inc. is a biotechnology company based in San Diego, California, established in 2019. It specializes in biomanufacturing solutions for high-value molecules, focusing on the development of specialty enzyme solutions and continuous manufacturing processes. The company offers a range of services, including biomanufacturing cartridges, fermentation, and the immobilization of cells and enzymes. Debut Biotechnology is dedicated to creating novel immobilization techniques for enzymes, achieving high success rates and providing immobilized enzymes for continuous manufacturing systems. Its innovative approach enables the production and modification of small and large molecules, catering primarily to the pharmaceutical and specialty chemical industries. By harnessing natural enzyme technologies, Debut aims to deliver sustainable and cost-effective ingredient solutions to its clients.

Azitra Inc. is a clinical-stage biopharmaceutical company based in Farmington, Connecticut, specializing in microbiome-based therapeutics for skin diseases. Founded in 2014, Azitra leverages extensive scientific research on the skin microbiome to develop innovative treatments for various adverse skin conditions. The company’s proprietary platform includes a microbial library of engineered bacterial strains, notably Staphylococcus epidermidis, which are screened for therapeutic properties. In collaboration with researchers from Yale University and the Jackson Laboratory, Azitra employs advanced technologies such as artificial intelligence and machine learning to analyze and predict the efficacy of its strains. The company focuses on precision dermatology by developing live biotherapeutic products and engineered proteins for topical application, aiming to address unmet medical needs in the dermatological field.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.

Solugen, Inc. is a specialty chemicals company based in Houston, Texas, founded in 2016. It focuses on producing industrial chemicals through the application of biotechnology and green chemistry, specifically utilizing plant-derived substitutes to replace petroleum-based products. The company offers a range of products, including BioPeroxide, a carbon-negative hydrogen peroxide, and BioChelate, a biodegradable chelant. Other offerings include ScavSol, a multivalent metal sequestrant for energy applications, ScaleSol, an alternative to phosphonates for scale control, and CorrSol, which addresses corrosion and fouling. Solugen's innovative approach combines fermentation and petrochemical processing along with advancements in synthetic biology and enzymatic technology, enabling it to create environmentally friendly chemicals from bio-based feedstocks. Its solutions cater to diverse industries such as agriculture, cleaning, energy, and water, contributing to reduced costs and lower carbon emissions while promoting sustainability.

Theator Inc. is a company that specializes in developing a surgical intelligence platform designed to enhance surgeon performance through the use of artificial intelligence and computer vision. Founded in 2018 and based in San Mateo, California, Theator offers a product known as Minutes, which includes content management software and a visual operative report with analytics. This platform analyzes and houses video data from surgical procedures, allowing surgeons to review and learn from past surgeries for educational purposes. By extracting and annotating key moments from real-world procedures, Theator empowers surgeons to gain insights into their performance and fosters a culture of continuous improvement in the operating room. The company's partnerships with innovative surgeons and hospitals aim to create a more transparent surgical environment while elevating surgical expertise.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, founded in 2016. It specializes in the development of sustainable performance materials derived from microalgae and biobased oils. The company focuses on innovating materials at a molecular level, utilizing its expertise in molecular foundry, chemistry, material science, and fabrication technology. Checkerspot aims to expand the range of molecular building blocks available for high-performance materials, particularly in industrial applications such as polyurethanes and textile finishes. Through its pioneering approach, Checkerspot contributes to the advancement of sustainable materials in various industries.

Founded in 2018, Terray Therapeutics is a biotechnology company based in Pasadena, California. It integrates experimentation and computation to enhance small molecule drug discovery, focusing on intractable diseases. The company's platform generates precise data through a rapid design-make-test-analyze cycle, enabling efficient exploration of chemical space.

Hi Fidelity Genetics LLC is a startup based in Durham, North Carolina, focused on developing innovative hardware and software for plant-breeding applications. The company specializes in creating tools that measure and predict plant traits, which are essential for enhancing productivity in agriculture. As the global population increases and climate change poses challenges to food supply, Hi Fidelity Genetics aims to democratize seed breeding and provide effective genetic modification services. Their technology seeks to improve the profitability of producers while maintaining sufficient food supplies, thereby addressing pressing agricultural needs in a changing environment.

Abridge is a healthcare technology company that uses generative AI to automate transcription and summarization of medical conversations. The platform turns patient-clinician discussions into structured clinical notes in real time and integrates with electronic health record systems. By reducing manual note-taking, it helps clinicians capture key details while producing clear summaries for patients, and ensures documentation is added to patient records. Abridge emphasizes data security and patient privacy, complies with healthcare regulations, and provides a customizable interface aligned with clinical workflows and patient needs.

Founded in 2018, Dyno Therapeutics specializes in developing adeno-associated virus (AAV) vectors for in vivo gene therapy delivery. The company's proprietary platform combines DNA synthesis of AAV capsids with sequencing and machine learning to create novel vectors tailored for safe, efficient, and targeted therapeutic solutions.

Visla Labs Inc. is a San Francisco-based company established in 2018 that focuses on developing an artificial intelligence platform tailored for the radiology and healthcare sectors. The company aims to innovate and enhance healthcare delivery through advanced AI technologies, positioning itself as a key player in the evolving landscape of medical diagnostics and patient care. With venture capital support, Visla Labs is poised for significant growth and is working towards achieving critical milestones in its development.

Tierra Biosciences, established in 2015 and based in San Francisco, specializes in developing cell-free technologies for molecule discovery. Its Next Generation Expression platform combines automation, computation, and high-throughput cell-free expression to express DNA from diverse microbial sources, enabling the production of molecules challenging to create using conventional laboratory methods. The company's protein platform integrates cell-free protein production with artificial intelligence, facilitating rapid, large-scale manufacturing akin to e-commerce simplicity. Formerly known as Synvitrobio, Inc., Tierra Biosciences changed its name in September 2018.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, founded in 2016. It specializes in the development of sustainable performance materials derived from microalgae and biobased oils. The company focuses on innovating materials at a molecular level, utilizing its expertise in molecular foundry, chemistry, material science, and fabrication technology. Checkerspot aims to expand the range of molecular building blocks available for high-performance materials, particularly in industrial applications such as polyurethanes and textile finishes. Through its pioneering approach, Checkerspot contributes to the advancement of sustainable materials in various industries.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, that focuses on developing gene therapies to enhance health and extend the lifespans of dogs and other domesticated animals. Founded in 2017, the company utilizes innovative approaches derived from research at the Wyss Institute at Harvard Medical School to create anti-aging therapies and address age-related diseases. By introducing new DNA instructions into the bodies of pets, Rejuvenate Bio aims to offer solutions for chronic conditions and improve overall well-being. The company's gene therapy pipeline is designed to target specific diseases and leverage clinically validated gene targets to ensure effective and lasting results.

Sepsis Scout is a developer of a wearable patch designed to predict the onset of sepsis in high-risk patients in home care settings. Utilizing proprietary deep learning technology, the device aims to detect sepsis more accurately than current standards of care. By enabling patients to manage chronic illnesses effectively, Sepsis Scout's solution helps individuals stay out of the hospital and alleviates the fear and uncertainty associated with serious health conditions. The company's focus on artificial intelligence and wearables positions it at the forefront of innovative healthcare solutions.

Azitra Inc. is a clinical-stage biopharmaceutical company based in Farmington, Connecticut, specializing in microbiome-based therapeutics for skin diseases. Founded in 2014, Azitra leverages extensive scientific research on the skin microbiome to develop innovative treatments for various adverse skin conditions. The company’s proprietary platform includes a microbial library of engineered bacterial strains, notably Staphylococcus epidermidis, which are screened for therapeutic properties. In collaboration with researchers from Yale University and the Jackson Laboratory, Azitra employs advanced technologies such as artificial intelligence and machine learning to analyze and predict the efficacy of its strains. The company focuses on precision dermatology by developing live biotherapeutic products and engineered proteins for topical application, aiming to address unmet medical needs in the dermatological field.

Elemental Machines, Inc., founded in 2014 and based in Cambridge, Massachusetts, specializes in providing a smart lab platform designed to enhance laboratory operations in science-based industries. The company's innovative technology continuously monitors equipment and environmental variables, delivering data-driven insights that foster improved research, development, and manufacturing outcomes. By utilizing intelligent sensors, the platform visualizes the entire testing environment and issues alerts for any anomalous results, thereby ensuring experimental reproducibility. This capability allows clients to refine and accelerate their work across all phases of product innovation, ultimately leading to greater clarity, transparency, and consistency in laboratory processes.

Elemental Machines, Inc., founded in 2014 and based in Cambridge, Massachusetts, specializes in providing a smart lab platform designed to enhance laboratory operations in science-based industries. The company's innovative technology continuously monitors equipment and environmental variables, delivering data-driven insights that foster improved research, development, and manufacturing outcomes. By utilizing intelligent sensors, the platform visualizes the entire testing environment and issues alerts for any anomalous results, thereby ensuring experimental reproducibility. This capability allows clients to refine and accelerate their work across all phases of product innovation, ultimately leading to greater clarity, transparency, and consistency in laboratory processes.

Hi Fidelity Genetics LLC is a startup based in Durham, North Carolina, focused on developing innovative hardware and software for plant-breeding applications. The company specializes in creating tools that measure and predict plant traits, which are essential for enhancing productivity in agriculture. As the global population increases and climate change poses challenges to food supply, Hi Fidelity Genetics aims to democratize seed breeding and provide effective genetic modification services. Their technology seeks to improve the profitability of producers while maintaining sufficient food supplies, thereby addressing pressing agricultural needs in a changing environment.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Solugen, Inc. is a specialty chemicals company based in Houston, Texas, founded in 2016. It focuses on producing industrial chemicals through the application of biotechnology and green chemistry, specifically utilizing plant-derived substitutes to replace petroleum-based products. The company offers a range of products, including BioPeroxide, a carbon-negative hydrogen peroxide, and BioChelate, a biodegradable chelant. Other offerings include ScavSol, a multivalent metal sequestrant for energy applications, ScaleSol, an alternative to phosphonates for scale control, and CorrSol, which addresses corrosion and fouling. Solugen's innovative approach combines fermentation and petrochemical processing along with advancements in synthetic biology and enzymatic technology, enabling it to create environmentally friendly chemicals from bio-based feedstocks. Its solutions cater to diverse industries such as agriculture, cleaning, energy, and water, contributing to reduced costs and lower carbon emissions while promoting sustainability.